Cited by 1,110Liver Disease Diagnosis and TreatmentInflammasome and immune disordersLiver physiology and pathology

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Open access

Mridha, Auvro R., Wree, Alexander, Robertson, Avril A.B., Yeh, Matthew M., Johnson, Casey D., Van Rooyen, Derrick M., Haczeyni, Fahrettin, Teoh, Narci C.-H., Savard, Christopher, Ioannou, George N., Masters, Seth L., Schroder, Kate, Cooper, Matthew A., Feldstein, Ariel E., Farrell, Geoffrey C.·2017·Journal of Hepatology

DOI 10.1016/j.jhep.2017.01.022PMC PMC6536116

Open this paper in CoChat — free account

Abstract

Background & aims NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis.Methods We fed foz/foz and wild-type mice an atherogenic diet for 16weeks, gavaged MCC950 or vehicle until 24weeks, then determined NAFLD phenotype. In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6weeks and determined the effects on liver fibrosis.Results In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1β, active caspase-1 and IL-1β increased at 24weeks, in association with cholesterol crystal formation and NASH pathology; plasma IL-1β, IL-6, MCP-1, ALT/AST all increased. MCC950 treatment normalized hepatic caspase 1 and IL-1β expression, plasma IL-1β, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathology, and liver fibrosis. In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1β; MCC950 abolished this, and the associated neutrophil migration. MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1β, lowered numbers of macrophages and neutrophils in the liver, and improved liver fibrosis.Conclusion MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice. This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells. MCC950 reduced liver fibrosis in MCD-fed mice. Targeting NLRP3 is a logical direction in pharmacotherapy of NASH.Lay summary Fatty liver disease caused by being overweight with diabetes and a high risk of heart attack, termed non-alcoholic steatohepatitis (NASH), is the most common serious liver disease with no current treatment. There could be several causes of inflammation in NASH, but activation of a protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a role. Here we show that cholesterol crystals could be one pathway to activate the inflammasome in NASH. We used a drug called MCC950, which has already been shown to block NLRP3 activation, in an attempt to reduce liver injury in NASH. This drug partly reversed liver inflammation, particularly in obese diabetic mice that most closely resembles the human context of NASH. In addition, such dampening of liver inflammation in NASH achieved with MCC950 partly reversed liver scarring, the process that links NASH to the development of cirrhosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2017.01.022

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Inflammasomes
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Self-citation
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Self-citation
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation
Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039
NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Hepatology · doi:10.1002/hep.26592 · Cited by 945
Self-citation
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
Cusi, K. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 940

Flagged first, then by citations

Show all 49 references

Sorted by citations

Items 401–500 of 999

Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances
Ding, Z., Wang, L., Sun, J., Zheng, L., Tang, Y., & Tang, H. H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1526206 · Cited by 35
Involvement of Nucleotide-Binding Oligomerization Domain-Like Receptor Family Pyrin Domain Containing 3 Inflammasome in the Pathogenesis of Liver Diseases
Shi, C., Yang, H., & Zhang, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00139 · Cited by 36
Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3
Ruan, S., Han, C., Sheng, Y., Wang, J., Zhou, X., Guan, Q., Li, W., Zhang, C., & Yang, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108126 · Cited by 34
Estrogen Receptor α Regulates Metabolic-Associated Fatty Liver Disease by Targeting NLRP3–GSDMD Axis-Mediated Hepatocyte Pyroptosis
Gao, X., Liu, S., Tan, L., Ding, C., Fan, W., Gao, Z., Li, M., Tang, Z., Wu, Y., Xu, L., et al. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c05400 · Cited by 34
Hyperlipidemia May Synergize with Hypomethylation in Establishing Trained Immunity and Promoting Inflammation in NASH and NAFLD
Drummer, C., Saaoud, F., Sun, Y., Atar, D., Xu, K., Lu, Y., Shao, Y., Johnson, C., Liu, L., Shen, H., et al. (2021) · Journal of Immunology Research · doi:10.1155/2021/3928323 · Cited by 34
Self-citation
A potential link between plasma short‑chain fatty acids, TNF‑α level and disease progression in non‑alcoholic fatty liver disease: A retrospective study
Xiong, J., Chen, X., Zhao, Z., Liao, Y., Zhou, T., & Xiang, Q. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11536 · Cited by 36
NLRP3 Inflammasome and Caspase-1/11 Pathway Orchestrate Different Outcomes in the Host Protection Against Trypanosoma cruzi Acute Infection
Paroli, A. F., Gonzalez, P. V., Díaz-Luján, C. M., Onofrio, L. I., Arocena, A. R., Cano, R. C., Silva, E. A. C., & Gea, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00913 · Cited by 33
Endothelial Dysfunction and Liver Cirrhosis: Unraveling of a Complex Relationship
Nesci, A., Ruggieri, V., Manilla, V., Spinelli, I., Santoro, L., Giorgio, A. D., Santoliquido, A., & Ponziani, F. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312859 · Cited by 34
Exposure to environmental black carbon exacerbates nasal epithelial inflammation via the reactive oxygen species (ROS)–nucleotide‐binding, oligomerization domain–like receptor family, pyrin domain containing 3 (NLRP3)–caspase‐1–interleukin 1β (IL‐1β) pathway
Li, Y., Ouyang, Y., Jiao, J., Xu, Z., & Zhang, L. (2020) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22669 · Cited by 33
The Purinergic P2X7 Receptor-NLRP3 Inflammasome Pathway: A New Target in Alcoholic Liver Disease?
Daré, B. L., Ferron, P., & Gicquel, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042139 · Cited by 35
Saikosaponin-d protects against liver fibrosis by regulating the estrogen receptor-β/NLRP3 inflammasome pathway
Lin, L., Zhou, M., Que, R., Chen, Y., Liu, X., Zhang, K., Shi, Z., & Li, Y. (2021) · Biochemistry and Cell Biology · doi:10.1139/bcb-2020-0561 · Cited by 33
The crosstalk between NLRP3 inflammasome and gut microbiome in atherosclerosis
Zhang, X., Yu, Z., Chen, J., Li, X., Wang, Z.-P., Wu, M., & Liu, L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106289 · Cited by 36
CREBH alleviates mitochondrial oxidative stress through SIRT3 mediating deacetylation of MnSOD and suppression of Nlrp3 inflammasome in NASH
Zhang, J., Zhao, Y., Wang, S., Li, G., & Xu, K. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.07.018 · Cited by 33
Salvianolic acid B ameliorates non-alcoholic fatty liver disease by inhibiting hepatic lipid accumulation and NLRP3 inflammasome in ob/ob mice
Meng, L., Zheng, J.-Y., Qiu, Y.-H., Li, Z., Zheng, J.-Y., Liu, Y., Miao, X.-L., & Lu, X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109099 · Cited by 33
Inhibition of the NLRP3 inflammasome improves lifespan in animal murine model of Hutchinson–Gilford Progeria
González‐Dominguez, A., Montañez, R., Castejón‐Vega, B., Nuñez‐Vasco, J., Lendines‐Cordero, D., Wang, C., Mbalaviele, G., Navarro‐Pando, J. M., Alcocer‐Gómez, E., & Cordero, M. D. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114012 · Cited by 32
Autophagy: A Cellular Guardian against Hepatic Lipotoxicity
Sinha, R. A. (2023) · Genes · doi:10.3390/genes14030553 · Cited by 33
The research progression of direct NLRP3 inhibitors to treat inflammatory disorders
Chen, X., Zhang, P., Zhang, Y. L., Wei, M., Tian, T., Zhu, D., Guan, Y., Wei, W., & Ma, Y. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104810 · Cited by 32
The Role of Cannabidiol in Liver Disease: A Systemic Review
Chen, S., & Kim, J.-K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042370 · Cited by 36
Plant‐derived flavonoids are a potential source of drugs for the treatment of liver fibrosis
Zhao, B., Liu, K., Liu, X., Li, Q., Li, Z., Xi, J., Xie, F., & Li, X. (2024) · Phytotherapy Research · doi:10.1002/ptr.8193 · Cited by 33
NLRP3 Inflammasome Activation in Liver Disorders: From Molecular Pathways to Therapeutic Strategies
Ma, W., Wang, Y., & Liu, J. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s532908 · Cited by 38
Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease
Willebrords, J., Maes, M., Pereira, I. V. A., da Silva, T. C., Govoni, V. M., Lopes, V. V., Yanguas, S. C., Shestopalov, V. I., Nogueira, M. S., de Castro, I. A., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.12.013 · Cited by 32
Matrine Protects Against MCD-Induced Development of NASH via Upregulating HSP72 and Downregulating mTOR in a Manner Distinctive From Metformin
Mahzari, A., Li, S., Zhou, X., Li, D., Fouda, S., Alhomrani, M., Alzahrani, W., Robinson, S. R., & Ye, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00405 · Cited by 32
Formononetin protects against concanavalin-A-induced autoimmune hepatitis in mice through its anti-apoptotic and anti-inflammatory properties
Liu, G., Zhao, W., Bai, J., Cui, J., Liang, H., & Lu, B. (2021) · Biochemistry and Cell Biology · doi:10.1139/bcb-2020-0197 · Cited by 32
Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma
Rajesh, Y., & Sarkar, D. (2020) · Cancers · doi:10.3390/cancers12051290 · Cited by 33
Porphyromonas gingivalis exacerbates the progression of fatty liver disease via CD36-PPARγ pathway
Ahn, J., Yang, J. W., Oh, S., Shin, Y. Y., Kang, M., Park, H. R., Seo, Y., & Kim, H. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.6.050 · Cited by 36
Carbohydrates deteriorate fatty liver by activating the inflammatory response
Gao, Y., Hua, R., Hu, K., & Wang, Z. (2021) · Nutrition Research Reviews · doi:10.1017/s0954422421000202 · Cited by 31
Therapeutic modulation of the liver immune microenvironment
Tilg, H., Adolph, T. E., & Tacke, F. (2023) · Hepatology · doi:10.1097/hep.0000000000000386 · Cited by 32
Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications
Yu, L., Gao, F., Li, Y., Su, D., Han, L., Li, Y., Zhang, X., & Feng, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116724 · Cited by 39
Dietary cholesterol does not break your heart but kills your liver
Püschel, G. P., & Henkel, J. (2018) · Porto Biomedical Journal · doi:10.1016/j.pbj.0000000000000012 · Cited by 31
Connexin and Pannexin (Hemi)Channels: Emerging Targets in the Treatment of Liver Disease
Cooreman, A., Campenhout, R. V., Ballet, S., Annaert, P., Bossche, B. V. D., Colle, I. O., Cogliati, B., & Vinken, M. (2018) · Hepatology · doi:10.1002/hep.30306 · Cited by 31
Selective Activation of Cannabinoid Receptor 2 Attenuates Myocardial Infarction via Suppressing NLRP3 Inflammasome
Yu, W. Y., Jin, G., Zhang, J., & Wei, W. (2018) · Inflammation · doi:10.1007/s10753-018-0945-x · Cited by 31
Silybin Restored CYP3A Expression through the Sirtuin 2/Nuclear Factor κ-B Pathway in Mouse Nonalcoholic Fatty Liver Disease
Zhang, R., Xu, D., Zhang, Y., Wang, R., Yang, N., Lou, Y., Zhao, H., Aa, J., Wang, G., & Xie, Y. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000438 · Cited by 31
The Role of Endoplasmic Reticulum Stress and NLRP3 Inflammasome in Liver Disorders
Lü, X., Huang, H., Fu, X., Chen, C., Liu, H., Wang, H., & Wu, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073528 · Cited by 31
Programmed Cell Death in Liver Fibrosis
Gao, R., Tang, H., & Mao, J. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s427868 · Cited by 32
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Dong, Q., Bao, H., Wang, J., Shi, W., Zou, X., Sheng, J., Gao, J., Guan, C., Xia, H., Li, J., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1120621 · Cited by 31
S1P/S1PR1 axis promotes macrophage M1 polarization through NLRP3 inflammasome activation in Lupus nephritis
Tian, J., Chang, S., Wang, J., Chen, J., Xu, H., Huang, T., Wang, J., Kang, J., Fan, W., & Wang, Y. (2023) · Molecular Immunology · doi:10.1016/j.molimm.2023.06.006 · Cited by 30
Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor)
Zhang, L., Chen, J., Yang, X., Shen, C., Huang, J., Zhang, D., Liu, N., Liu, C., Zhong, Y., Chen, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01727-7 · Cited by 32
Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease
Buchynskyi, M., Kamyshna, I., Halabitska, I., Petakh, P., Kunduzova, O., Oksenych, V., & Kamyshnyi, O. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1577724 · Cited by 30
Therapeutics administered during ex vivo liver machine perfusion: An overview
Buchwald, J. E., Xu, J., Bozorgzadeh, A., & Martins, P. N. A. (2020) · World Journal of Transplantation · doi:10.5500/wjt.v10.i1.1 · Cited by 30
High Glucose‐Aggravated Hepatic Insulin Resistance: Role of the NLRP3 Inflammasome in Kupffer Cells
Zheng, T., Wang, Q., Dong, Y., Ma, W., Zhang, Y., Zhao, Y., Bian, F., & Chen, L. (2020) · Obesity · doi:10.1002/oby.22821 · Cited by 30
Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target
Çolak, Y., Hasan, B., ŞENATEŞ, B. E., Tandon, K. S., Zervos, X. B., Menzo, E. L., & Erim, T. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101710 · Cited by 28
Paeoniflorin Ameliorates Diabetic Liver Injury by Targeting the TXNIP-Mediated NLRP3 Inflammasome in Db/Db Mice
Wang, A., Gong, Y., Pei, Z., Jiang, L., Xia, L., & Wu, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108792 · Cited by 31
Role of NLRP3 inflammasome in systemic sclerosis
Lin, C., Jiang, Z., Cao, L., Zou, H., & Zhu, X. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02889-5 · Cited by 33
Qingrequzhuo capsule alleviated methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice through regulating gut microbiota, enhancing gut tight junction and inhibiting the activation of TLR4/NF-κB signaling pathway
Lv, S., Zhang, Z., Su, X., Li, W., Wang, X., Pan, B., Li, H., Zhang, H., & Wang, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1106875 · Cited by 30
Small intestinal bacterial overgrowth and orocecal transit time in patients of nonalcoholic fatty liver disease
Shi, H., Mao, L., Wang, L., Quan, X., Xu, X., Cheng, Y., Zhu, S., & Dai, F. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002157 · Cited by 29
Isoquercitrin Attenuates Steatohepatitis by Inhibition of the Activated NLRP3 Inflammasome through HSP90
Ma, J., Li, M., Yang, T., Deng, Y., Ding, Y., Guo, T., & Shang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108795 · Cited by 31
Blockade of C5aR1 alleviates liver inflammation and fibrosis in a mouse model of NASH by regulating TLR4 signaling and macrophage polarization
Jiang, K., Lu, S., Li, D., Liu, M., Hu, J., Lei, B., Wang, S., Long, K., He, S., & Zhong, F. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02002-w · Cited by 29
Hepatocyte NLRP3 interacts with PKCε to drive hepatic insulin resistance and steatosis
Qin, W., & Weng, J. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.06.003 · Cited by 29
The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
Vachliotis, I. D., & Pοlyzos, S. A. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00657-5 · Cited by 31
Dexmedetomidine promotes liver regeneration in mice after 70% partial hepatectomy by suppressing NLRP3 inflammasome not TLR4/NFκB
Lv, M., Zeng, H., He, Y., Zhang, J., & Tan, G. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.10.030 · Cited by 30
Nobiletin alleviates palmitic acid‑induced NLRP3 inflammasome activation in a sirtuin 1‑dependent manner in AML‑12 cells
Peng, Z., Li, X., Xing, D., Du, X., Wang, Z., Liu, G., & Li, X. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9615 · Cited by 29
Deletion of Perilipin 5 Protects against Hepatic Injury in Nonalcoholic Fatty Liver Disease via Missing Inflammasome Activation
Asimakopoulou, A., Engel, K. M., Gaßler, N., Bracht, T., Sitek, B., Buhl, E. M., Kalampoka, S., Pinoé-Schmidt, M., van Helden, J., Schiller, J., et al. (2020) · Cells · doi:10.3390/cells9061346 · Cited by 29
IL-1 β Pretreatment Improves the Efficacy of Mesenchymal Stem Cells on Acute Liver Failure by Enhancing CXCR4 Expression
Nie, H., An, F., Mei, J., Cheng, Y., Zhan, Q., & Zhang, Q. (2020) · Stem Cells International · doi:10.1155/2020/1498315 · Cited by 29
HDAC 6 inhibitor ACY 1215 inhibits the activation of NLRP 3 inflammasome in acute liver failure by regulating the ATM/F ‐actin signalling pathway
Chen, Q., Wang, Y., Jiao, F., Cao, P., Shi, C., Pei, M., Wang, L., & Gong, Z. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16751 · Cited by 28
NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation
Wang, Z., Xu, G., Li, Z., Xiao, X., Tang, J., & Bai, Z. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s344071 · Cited by 29
Linking nutrient sensing, mitochondrial function, and PRR immune cell signaling in liver disease
Kemper, C., & Sack, M. N. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.09.002 · Cited by 27
Ursolic acid alleviates Kupffer cells pyroptosis in liver fibrosis by the NOX2/NLRP3 inflammasome signaling pathway
Wan, Y., Zhang, W., Huang, C., Jian, J., Zhang, Y., Liu, Q., Chen, P., & Zhu, X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109321 · Cited by 28
Caveolin-1 ameliorates acetaminophen-aggravated inflammatory damage and lipid deposition in non-alcoholic fatty liver disease via the ROS/TXNIP/NLRP3 pathway
Jiang, X., Li, Y., Fu, D., You, T., Wu, S., Xin, J., Wen, J., Huang, Y., & Hu, C. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109558 · Cited by 29
Tanshinone I specifically suppresses NLRP3 inflammasome activation by disrupting the association of NLRP3 and ASC
Zhao, J., Liu, H., Hong, Z., Mu, W., Mu, W., Hou, X., Xu, G., 方志娥, Ren, L., Liu, T., et al. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00671-0 · Cited by 32
The role of gut microbiota in intestinal and liver diseases
Hrncir, T., Hrncirova, L., Kverka, M., & Tlaskalová‐Hogenová, H. (2018) · Laboratory Animals · doi:10.1177/0023677218818605 · Cited by 29
A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?
Tilg, H., Effenberger, M., & Adolph, T. E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1681397 · Cited by 28
Examination of the role of necroptotic damage-associated molecular patterns in tissue fibrosis
Liu, X., Lu, F., & Chen, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.886374 · Cited by 30
IFNγ-IL12 axis regulates intercellular crosstalk in metabolic dysfunction-associated steatotic liver disease
Friedline, R. H., Noh, H. L., Suk, S., Albusharif, M., Dağdeviren, S., Saengnipanthkul, S., Kim, B. K., Kim, A. M., Kim, L. H., TAUER, L. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49633-y · Cited by 31
Immune markers of severe acute pancreatitis
Lee, P. J., Papachristou, G. I., Speake, C., & Lacy‐Hulbert, A. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001053 · Cited by 33
NLRP3 inflammasome pathway involved in the pathogenesis of metabolic associated fatty liver disease
Osman, H. A., Abuhamdah, S. M. A., Hassan, M. H., Hashim, A. A., Ahmed, A. E., Elsayed, S. S., El-Sawy, S. A., Gaber, M. A., & Abdelhady, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-69764-y · Cited by 28
Role of spleen tyrosine kinase in liver diseases
Kurniawan, D. W., Storm, G., Prakash, J., & Bansal, R. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i10.1005 · Cited by 29
Pathogenesis of NASH and Promising Natural Products
Leng, Y., Zhang, M., Luo, J., & Zhang, H. (2021) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(21)60002-x · Cited by 29
4-Acetylantroquinonol B ameliorates nonalcoholic steatohepatitis by suppression of ER stress and NLRP3 inflammasome activation
Yen, I., Tu, Q.-W., Chang, T., Lin, P.-H., Li, Y., & Lee, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111504 · Cited by 28
Simultaneous Modulation of NLRP3 Inflammasome and Nrf2/ARE Pathway Rescues Thioacetamide-Induced Hepatic Damage in Mice: Role of Oxidative Stress and Inflammation
Dwivedi, D. K., & Jena, G. (2021) · Inflammation · doi:10.1007/s10753-021-01571-3 · Cited by 28
Oxidized Lipids: Common Immunogenic Drivers of Non-Alcoholic Fatty Liver Disease and Atherosclerosis
Hoebinger, C., Rajcic, D., & Hendrikx, T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.824481 · Cited by 32
Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
Welch, R. D., Billon, C., Losby, M., Bedia‐Diaz, G., Fang, Y., Avdagic, A., Elgendy, B., Burris, T. P., & Griffett, K. (2022) · Metabolites · doi:10.3390/metabo12030238 · Cited by 28
Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease
Deng, K., Huang, X., Lei, F., Zhang, X., Zhang, P., She, Z., Cai, J., Ji, Y., & Li, H. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00123.2022 · Cited by 31
The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity
Papadakos, S. P., Dedes, N., Kouroumalis, E., & Theocharis, S. E. (2022) · Cancers · doi:10.3390/cancers14133150 · Cited by 28
Loganin Prevents Hepatic Steatosis by Blocking NLRP3 Inflammasome Activation
Jang, J. H., Yang, G., Seok, J. K., Kang, H. C., Cho, Y., Lee, H. S., & Lee, J. Y. (2022) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2022.077 · Cited by 28
JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders
Ambrus-Aikelin, G., Takeda, K., Joetham, A., Lazic, M., Povero, D., Santini, A. M., Pranadinata, R., Johnson, C. D., McGeough, M. D., Beasley, F. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39805-z · Cited by 28
Self-citation
Pigment Nephropathy: Novel Insights into Inflammasome-Mediated Pathogenesis
Giuliani, K. T. K., Kassianos, A. J., Healy, H. G., & Gois, P. H. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081997 · Cited by 29
Oxymatrine alleviates high-fat diet/streptozotocin-induced non-alcoholic fatty liver disease in C57BL/6 J mice by modulating oxidative stress, inflammation and fibrosis
Lou, D., Fang, Q., He, Y., Ma, R., Wang, X., Li, H., & Qi, M.-Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116491 · Cited by 31
The water extract of Sophorae tonkinensis Radix et Rhizoma alleviates non-alcoholic fatty liver disease and its mechanism
Zhao, Q., Wei, M., Zhang, S., Huang, Z., Lü, B., & Ji, L. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153270 · Cited by 27
Notch-activated mesenchymal stromal/stem cells enhance the protective effect against acetaminophen-induced acute liver injury by activating AMPK/SIRT1 pathway
Yu, M., Zhou, M., Li, J., Zong, R., Yan, Y., Kong, L., Zhu, Q., & Li, C.-Y. (2022) · Stem cell research & therapeutics · doi:10.1186/s13287-022-02999-6 · Cited by 27
Theabrownin ameliorates liver inflammation, oxidative stress, and fibrosis in MCD diet-fed C57BL/6J mice
Zhen, Q., Liang, Q., Wang, H., Zheng, Y., Lu, Z., Bian, C., Zhao, X., & Guo, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1118925 · Cited by 27
The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer—Challenges and opportunities
Kohlhepp, M. S., Liu, H., Tacke, F., & Guillot, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1129831 · Cited by 27
Exercise training-attenuated insulin resistance and liver injury in elderly pre-diabetic patients correlates with NLRP3 inflammasome
Zhang, T., Tian, J., Fan, J., Liu, X., & Wang, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1082050 · Cited by 28
Disrupting phosphatase SHP2 in macrophages protects mice from high-fat diet-induced hepatic steatosis and insulin resistance by elevating IL-18 levels
Liu, W., Yin, Y., Wang, M., Fan, T., Zhu, Y., Shen, L., Peng, S., Gao, J., Deng, G., Meng, X., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011840 · Cited by 28
Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis
Li, N., Jiang, X., Zhang, R., Ye, N., Tang, M., Cai, X., Su, K., Peng, J., Zhang, X., Zhao, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00696 · Cited by 26
Endotoxin Inflammatory Action on Cells by Dysregulated-Immunological-Barrier-Linked ROS-Apoptosis Mechanisms in Gut–Liver Axis
Dumitru, A., Matei, E., Cozaru, G. C., Chisoi, A., Alexandrescu, L., Popescu, R. C., Pundiche, M. B., Dumitru, E., Rugină, S., & Tocia, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052472 · Cited by 26
NLRP3 deficiency protects against acetaminophen‑induced liver injury by inhibiting hepatocyte pyroptosis
Yuan, X., Chen, P., Luan, X., Yu, C., Miao, L., Zuo, Y., Liu, A., Sun, T., & Di, G. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13185 · Cited by 29
Mitochondrial ROS, a trigger for mitochondrial dysfunction and inflammasome activation and a therapeutic target in liver diseases
Jaara, H. S., & Torres, S. (2024) · Exploration of Digestive Diseases · doi:10.37349/edd.2024.00062 · Cited by 30
Lactiplantibacillus plantarum FRT4 protects against fatty liver hemorrhage syndrome: regulating gut microbiota and FoxO/TLR-4/NF-κB signaling pathway in laying hens
Li, D., Meng, K., Liu, G., Wen, Z., Han, Y., Liu, W., Xu, X. J., Song, L., Cai, H., & Yang, P. (2025) · Microbiome · doi:10.1186/s40168-025-02083-0 · Cited by 27
Human metapneumovirus activates NOD-like receptor protein 3 inflammasome via its small hydrophobic protein which plays a detrimental role during infection in mice
Lê, V. B., Dubois, J., Couture, C., Cavanagh, M.-H., Uyar, O., Pizzorno, A., Rosa‐Calatrava, M., Hamelin, M., & Boivin, G. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007689 · Cited by 26
Involvement of the Autophagy-ER Stress Axis in High Fat/Carbohydrate Diet-Induced Nonalcoholic Fatty Liver Disease
Zhou, X., Fouda, S., Li, D., Zhang, K., & Ye, J. (2020) · Nutrients · doi:10.3390/nu12092626 · Cited by 29
Regulation of the Immune Microenvironment by an NLRP3 Inhibitor Contributes to Attenuation of Acute Right Ventricular Failure in Rats with Pulmonary Arterial Hypertension
Guo, L., Qin, G., Cao, Y., Yang, Y., Dai, S., Wang, L., & Wang, E. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s336964 · Cited by 26
Red yeast rice ameliorates non-alcoholic fatty liver disease through inhibiting lipid synthesis and NF-κB/NLRP3 inflammasome-mediated hepatic inflammation in mice
Zou, J., Yan, C., & Wan, J. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00573-z · Cited by 26
Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice
Silva-Veiga, F. M., Miranda, C. S., Vasques‐Monteiro, I. M. L., Souza-Tavares, H., Martins, F. F., Daleprane, J. B., & Souza‐Mello, V. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i17.1814 · Cited by 29
Regulatory Roles of Caspase-11 Non-Canonical Inflammasome in Inflammatory Liver Diseases
Yi, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094986 · Cited by 27
Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease
Teng, T., Qiu, S., Zhao, Y., Zhao, S., Sun, D., Hou, L., Li, Y., Zhou, K., Yu, X., Yang, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147841 · Cited by 26
Inhibiting NLRP3 signaling in aging podocytes improves their life- and health-span
Kaverina, N. V., Schweickart, R. A., Chan, G. C., Maggiore, J. C., Eng, D. G., Zeng, Y., McKinzie, S. R., Perry, H. S., Ali, A., O'Connor, C. L., et al. (2023) · Aging · doi:10.18632/aging.204897 · Cited by 27
Nicotinic acid attenuates experimental non-alcoholic steatohepatitis by inhibiting the NLRP3 inflammasome/pyroptosis pathway
Cardoso-Lezama, I., Fuentes-Figueroa, M. Á., Ramos‐Tovar, E., Márquez-Quiroga, L. V., Ortiz‐Fernández, A., Vargas-Pozada, E. E., Arellanes‐Robledo, J., Tsutsumi, V., & Muriel, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115762 · Cited by 27
Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase
Shi, W., Xu, G., Gao, Y., Zhao, J., Liu, T., Zhao, J. W., Yang, H., Wei, Z., Li, H., Xu, A., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04380-4 · Cited by 26
NLRP3 Inflammasome: A Novel Player in Metabolically Induced Inflammation—Potential Influence on the Myocardium
Sokolova, M., Ranheim, T., Louwe, M. C., Halvorsen, B. L., Yndestad, A., & Aukrust, P. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000704 · Cited by 27
Inflammation-related miRNAs in obesity, CVD, and NAFLD
Aghaei, S. M., & Hosseini, S. M. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156724 · Cited by 26

Authors: Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., Masters, S. L., Schroder, K., Cooper, M. A., Feldstein, A. E., & Farrell, G. C.
Affiliations: Australian National University (AU)
University of California San Diego (US)
The University of Queensland (AU)
University of Washington (US)
Walter and Eliza Hall Institute of Medical Research (AU)
Corresponding author: Farrell, Geoffrey C.
ORCID: Mridha, Auvro R.
Wree, Alexander
Robertson, Avril A.B.
Yeh, Matthew M.
Johnson, Casey D.
Haczeyni, Fahrettin
Savard, Christopher
Ioannou, George N.
Masters, Seth L.
Schroder, Kate
Cooper, Matthew A.
Feldstein, Ariel E.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2017-05
Volume: 66
Issue: 5
Pages: 1037-1046
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2017.01.022
PMC: PMC6536116
OpenAlex: W2585046292
Cited by: 1,110
References: 49
Citations by year: 2026: 117 · 2025: 147 · 2024: 126 · 2023: 150 · 2022: 160 · 2021: 143 · 2020: 121 · 2019: 61 · 2018: 70 · 2017: 14
FWCI: 57.20
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
ANU Open Research (Australian National University) (submittedVersion, cc-by-nc-nd)
RWTH Publications (RWTH Aachen) (submittedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (U01AA022489, R21AA023574)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK113592)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: NLRP3 inflammasome, MCC950, nonalcoholic steatohepatitis, liver fibrosis, liver inflammation, IL-1β, caspase-1, cholesterol crystals, Kupffer cells, macrophages, neutrophil migration, methionine-choline-deficient diet, atherogenic diet, myeloid cells
MeSH terms: NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Disease Models, Animal, Female, Furans, Hepatitis, Heterocyclic Compounds, 4 or More Rings, Indenes, Liver Cirrhosis, Experimental, Sulfonamides, Sulfones, NF-kappa B, Reactive Oxygen Species, Mice, Interleukin-1beta, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks